
ANIX Stock Forecast & Price Target
ANIX Analyst Ratings
Bulls say
Anixa Biosciences Inc. has established a strong intellectual property position through its patent for CAR-T technology, which bolsters its competitive advantage in the biotechnology sector. The completion of the final patient visits in its Phase 1 breast cancer vaccine trial marks a significant clinical milestone, with preliminary data indicating over 70% of participants achieving a desired immune response and acceptable safety levels. Additionally, the company's dual approach to oncology, focusing on both preventative measures in high-risk individuals and therapeutic methods for existing cancer patients, enhances its potential for innovative cancer control with reduced side effects compared to traditional therapies, positioning it favorably in the immuno-oncology landscape.
Bears say
Anixa Biosciences Inc. is facing challenges due to its limited revenue streams and reliance on developmental-stage products, which often require significant investment without guaranteed returns. The company’s pursuit of complex therapeutic developments in oncology is compounded by high research and development costs, creating financial strain and uncertainty regarding future profitability. Additionally, its dependency on successful outcomes in clinical trials poses further risk, as setbacks in these trials could lead to substantial declines in stock performance.
This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
ANIX Analyst Forecast & Price Prediction
Start investing in ANIX
Order type
Buy in
Order amount
Est. shares
0 shares